Cargando…

Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors

Immune checkpoints expressed on tumor cells may suppress the cytotoxicity of tumor-infiltrating lymphocytes (TILs) via interaction with their ligands. In the present study, checkpoint proteins and ligands, including programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), cluster of differentia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Yaolin, Cui, Guoyuan, Jiang, Zhongxiu, Li, Ning, Zhang, Xiaoye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365950/ https://www.ncbi.nlm.nih.gov/pubmed/30854074 http://dx.doi.org/10.3892/ol.2019.9910

Ejemplares similares

BTLA Expression in Stage I–III Non–Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes
por: Li, Xiangmin, et al.
Publicado: (2020)

SIRT1 overexpression protects non-small cell lung cancer cells against osteopontin-induced epithelial-mesenchymal transition by suppressing NF-κB signaling
por: Li, Xuejiao, et al.
Publicado: (2018)

Integrated omics and gene expression analysis identifies the loss of metabolite–metabolite correlations in small cell lung cancer
por: Yu, Li, et al.
Publicado: (2018)

MicroRNA‐155‐5p suppresses PD‐L1 expression in lung adenocarcinoma
por: Huang, Jiansheng, et al.
Publicado: (2020)

CD155 expression and its clinical significance in non-small cell lung cancer
por: Oyama, Rintaro, et al.
Publicado: (2022)

Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment
por: Wang, Rui-Bin, et al.
Publicado: (2020)

MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells
por: Zheng, Zhong, et al.
Publicado: (2019)

Psychogenic fever in a patient with small cell lung cancer: a case report
por: Xu, Mengdan, et al.
Publicado: (2015)

PD-L1/miR-155 Interplay in Pediatric High-Grade Glioma
por: Litak, Jakub, et al.
Publicado: (2022)

PD-L1 and c-MET expression and survival in patients with small cell lung cancer
por: Miao, Lulu, et al.
Publicado: (2017)

CD155 Cooperates with PD-1/PD-L1 to Promote Proliferation of Esophageal Squamous Cancer Cells via PI3K/Akt and MAPK Signaling Pathways
por: Tang, Xiyang, et al.
Publicado: (2022)

CD155 and Its Receptors as Targets for Cancer Therapy
por: Paolini, Rossella, et al.
Publicado: (2023)

PD‐L1 and CD47 co‐expression predicts survival and enlightens future dual‐targeting immunotherapy in non‐small cell lung cancer
por: Yang, Zhenlin, et al.
Publicado: (2021)

The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
por: Cai, Jiajing, et al.
Publicado: (2019)

Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy
por: Ali, Wael Abdullah Sultan, et al.
Publicado: (2021)

CD24, not CD47, negatively impacts upon response to PD‐1/L1 inhibitors in non–small‐cell lung cancer with PD‐L1 tumor proportion score < 50
por: Ozawa, Yuichi, et al.
Publicado: (2020)

MicroRNA‐326 negatively regulates CD155 expression in lung adenocarcinoma
por: Nakanishi, Takayuki, et al.
Publicado: (2023)

CD155 Overexpression Correlates With Poor Prognosis in Primary Small Cell Carcinoma of the Esophagus
por: Zhao, Kaikai, et al.
Publicado: (2021)

PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
por: Larsen, Trine Vilsbøll, et al.
Publicado: (2019)

Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8(+) Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer
por: Munari, Enrico, et al.
Publicado: (2021)

The Mechanism of miR-155/miR-15b Axis Contributed to Apoptosis of CD34+ Cells by Upregulation of PD-L1 in Myelodysplastic Syndromes
por: Cao, MeiWan, et al.
Publicado: (2023)

Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma
por: Ma, Ke, et al.
Publicado: (2020)

Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer
por: Lang, C., et al.
Publicado: (2022)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases
por: Sun, Chenglong, et al.
Publicado: (2020)

Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma
por: Wu, Tong, et al.
Publicado: (2023)

The Value of MicroRNA-155 as a Prognostic Factor for Survival in Non-Small Cell Lung Cancer: A Meta-Analysis
por: Wang, Fei, et al.
Publicado: (2015)

The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer
por: Sheng, Zhixin, et al.
Publicado: (2017)

Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients
por: Arrieta, Oscar, et al.
Publicado: (2017)

PD-L1 Expression and Survival among Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy()
por: Sorensen, Steffen Filskov, et al.
Publicado: (2016)

Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer
por: Ghiringhelli, François, et al.
Publicado: (2023)

Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer
por: Cui, Pengfei, et al.
Publicado: (2020)

Improved survival outcome with not-delayed radiotherapy and immediate PD-1/PD-L1 inhibitor for non-small-cell lung cancer patients with brain metastases
por: Yu, Yaner, et al.
Publicado: (2023)

The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer
por: Zens, Philipp, et al.
Publicado: (2022)

CD8(+) PD-1(+) T-cells and PD-L1(+) circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?
por: Kotsakis, Athanasios, et al.
Publicado: (2019)

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer
por: Inoue, Yusuke, et al.
Publicado: (2016)

Impact of immune checkpoint gene CD155 Ala67Thr and CD226 Gly307Ser polymorphisms on small cell lung cancer clinical outcome
por: Lee, Jang Hyuck, et al.
Publicado: (2021)

PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas
por: Zhang, Shuang, et al.
Publicado: (2020)

Increased Soluble CD155 in the Serum of Cancer Patients
por: Iguchi-Manaka, Akiko, et al.
Publicado: (2016)

CD155, an onco‐immunologic molecule in human tumors
por: Gao, Jian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hrqjvccps8o27gvsqp28mofjd1